


Ivabradine hydrochloride

Chemical Properties

CAS No. :	148849-67-6
Formula:	C ₂₇ H ₃₇ ClN ₂ O ₅
Molecular Weight:	505.05
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Ivabradine hydrochloride (S 16257-2) is a new If inhibitor (IC ₅₀ : 2.9 μM). Ivabradine Hydrochloride is the hydrochloride salt form of ivabradine, an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel blocker, with negative chronotropic activity. Upon administration, ivabradine selectively binds to the intracellular portion of the HCN channel pore and blocks HCN channels in the pacemaker cells within the sinoatrial (SA) node. This inhibits the If (funny) pacemaker ion current, prevents the inward flow and intracellular accumulation of positively charged ions, reduces pacemaker activity and slows diastolic depolarization.
Targets(IC ₅₀)	HCN Channel,Adrenergic Receptor
In vivo	Ivabradine treatment (10 mg/kg/d) induces long-term HRR, and that improves diastolic LV function probably involving attenuated hypoxia, reduced remodeling, and/or preserved nitric oxide bioavailability, resulting from processes triggered early after HRR initiation: angiogenesis and/or preservation of endothelial nitric oxide synthase expression[1]. Ivabradine causes a sustained 15-20% heart rate reduction, but has no effect on blood pressure. While ivabradine has no effect on endothelial function and vascular reactive oxygen species production in angiotensin II-treated rats, it improves both parameters in ApoE knockout mice. Ivabradine treatment leads to an attenuation of angiotensin II signaling and increased the expression of telomere-stabilizing proteins in ApoE knockout mice, which may explain its beneficial effects on the vasculature. The absence of these protective ivabradine effects in angiotensin II-infused rats may relate to the treatment duration or the presence of arterial hypertension[2].

Solubility Information

Solubility	DMSO: 250 mg/mL (495 mM),Sonication is recommended. Ethanol: 93 mg/mL (184.14 mM),Sonication is recommended. H ₂ O: 75 mg/mL (148.5 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.53 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may</i>

A DRUG SCREENING EXPERT

In vivo Formulation	<i>vary and should be modified based on specific experimental conditions.</i>
---------------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.980 mL	9.900 mL	19.800 mL
5 mM	0.396 mL	1.980 mL	3.960 mL
10 mM	0.198 mL	0.990 mL	1.980 mL
50 mM	0.0396 mL	0.198 mL	0.396 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Thollon C, et al. Br J Pharmacol, 1994,112(1):37-42.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481